Insider Trades53 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | Sell | RGEN | Jason K Garland | CFO | 530 | $150.00 | $8.3B | -16.23% | +45.81% | $79.5K | -2.74% | 10b5-1 | — |
| Jun 25, 2026 | Sell | RGEN | Jason K Garland | CFO | 733 | $145.00 | $8.3B | -16.23% | +45.81% | $106.3K | -3.65% | 10b5-1 | — |
| May 7, 2026 | Sell | RGEN | Brian Robb Douglass | CHIEF PRODUCT OFFICER | 334 | $126.43 | $8.3B | -16.23% | +45.81% | $42.2K | -4.01% | — | — |
| Apr 21, 2026 | Sell | RGEN | Olivier Loeillot | Chief Executive Officer | 3,832 | $140.00 | $8.3B | -16.23% | +45.81% | $536.5K | -6.60% | — | — |
| Mar 4, 2026 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 42 | $125.84 | $8.3B | -16.23% | +45.81% | $5.3K | -0.28% | — | — |
| Mar 4, 2026 | Sell | RGEN | James Bylund | Chief Operating Officer | 62 | $125.84 | $8.3B | -16.23% | +45.81% | $7.8K | -0.35% | — | — |
| Mar 2, 2026 | Sell | RGEN | Brian Robb Douglass | CHIEF PRODUCT OFFICER | 221 | $124.97 | $8.3B | -16.23% | +45.81% | $27.6K | -2.59% | — | — |
| Feb 27, 2026 | Sell | RGEN | Jason K Garland | CFO | 1,042 | $126.15 | $8.3B | -16.23% | +45.81% | $131.4K | -3.94% | — | — |
| Feb 27, 2026 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 1,367 | $126.19 | $8.3B | -16.23% | +45.81% | $172.5K | -4.32% | — | — |
| Feb 27, 2026 | Sell | RGEN | Olivier Loeillot | Chief Executive Officer | 1,954 | $125.63 | $8.3B | -16.23% | +45.81% | $245.5K | -2.73% | — | — |
| Feb 27, 2026 | Sell | RGEN | James Bylund | Chief Operating Officer | 3,911 | $126.39 | $8.3B | -16.23% | +45.81% | $494.3K | -9.41% | — | — |
| Nov 25, 2025 | Sell | RGEN | Olivier Loeillot | Chief Executive Officer | 7,041 | $170.00 | $8.3B | -16.23% | +45.81% | $1.2M | -16.40% | — | — |
| Nov 18, 2025 | Sell | RGEN | James Bylund | Chief Operating Officer | 2,191 | $151.21 | $8.3B | -16.23% | +45.81% | $331.3K | -9.24% | — | — |
| Oct 2, 2025 | Sell | RGEN | Olivier Loeillot | Chief Executive Officer | 1,248 | $145.23 | $8.3B | -16.23% | +45.81% | $181.2K | -2.82% | — | — |
| Sep 25, 2025 | Sell | RGEN | Jason K Garland | CFO | 412 | $121.68 | $8.3B | -16.23% | +45.81% | $50.1K | -2.99% | — | — |
| Sep 3, 2025 | Sell | RGEN | Olivier Loeillot | Chief Executive Officer | 2,506 | $116.18 | $8.3B | -16.23% | +45.81% | $291.1K | -5.37% | — | — |
| Apr 1, 2025 | Sell | RGEN | James Bylund | Chief Operating Officer | 454 | $128.50 | $8.3B | -16.23% | +45.81% | $58.3K | -1.88% | — | — |
| Mar 13, 2025 | Sell | RGEN | James Bylund | Chief Operating Officer | 175 | $142.44 | $8.3B | -16.23% | +45.81% | $24.9K | -0.72% | — | — |
| Mar 3, 2025 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 386 | $155.38 | $8.3B | -16.23% | +45.81% | $60.0K | -1.84% | — | — |
| Mar 3, 2025 | Sell | RGEN | James Bylund | Chief Operating Officer | 1,239 | $155.38 | $8.3B | -16.23% | +45.81% | $192.5K | -3.96% | — | — |
| Feb 27, 2025 | Sell | RGEN | Jason K Garland | CFO | 316 | $156.54 | $8.3B | -16.23% | +45.81% | $49.5K | -4.12% | — | — |
| Feb 27, 2025 | Sell | RGEN | Olivier Loeillot | Chief Executive Officer | 343 | $156.54 | $8.3B | -16.23% | +45.81% | $53.7K | -1.05% | — | — |
| Feb 27, 2025 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 391 | $156.54 | $8.3B | -16.23% | +45.81% | $61.2K | -3.25% | — | — |
| Feb 27, 2025 | Sell | RGEN | James Bylund | Chief Operating Officer | 1,285 | $156.54 | $8.3B | -16.23% | +45.81% | $201.2K | -6.41% | — | — |
| Feb 24, 2025 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 275 | $164.74 | $8.3B | -16.23% | +45.81% | $45.3K | -2.24% | — | — |
| Feb 24, 2025 | Sell | RGEN | James Bylund | Chief Operating Officer | 543 | $164.74 | $8.3B | -16.23% | +45.81% | $89.5K | -2.64% | — | — |
| Nov 20, 2024 | Sell | RGEN | Jason K Garland | CFO | 367 | $123.41 | $8.3B | -16.23% | +45.81% | $45.3K | -4.56% | — | — |
| Nov 20, 2024 | Sell | RGEN | Olivier Loeillot | Chief Executive Officer | 861 | $123.41 | $8.3B | -16.23% | +45.81% | $106.3K | -2.58% | — | — |
| Aug 2, 2024 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 7,323 | $157.60 | $8.3B | -16.23% | +45.81% | $1.2M | -15.84% | — | — |
| Aug 1, 2024 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 4,465 | $165.67 | $8.3B | -16.23% | +45.81% | $739.7K | -18.82% | — | — |
| Jun 14, 2024 | Buy | RGEN | Anthony Hunt | Chief Executive Officer | 2,000 | $124.08 | $8.3B | -16.23% | +45.81% | $248.2K | +1.23% | — | — |
| May 21, 2024 | Sell | RGEN | Anthony Hunt | Chief Executive Officer | 20,072 | $168.26 | $8.3B | -16.23% | +45.81% | $3.4M | -1.93% | — | — |
| May 14, 2024 | Sell | RGEN | Christine Gebski | — | 334 | $163.34 | $8.3B | -16.23% | +45.81% | $54.6K | -1.20% | — | — |
| May 14, 2024 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 534 | $163.34 | $8.3B | -16.23% | +45.81% | $87.2K | -2.20% | — | — |
| Apr 2, 2024 | Sell | RGEN | James Bylund | Chief Operating Officer | 444 | $182.95 | $8.3B | -16.23% | +45.81% | $81.2K | -2.11% | — | — |
| Mar 18, 2024 | Sell | RGEN | Anthony Hunt | Chief Executive Officer | 2,000 | $194.25 | $8.3B | -16.23% | +45.81% | $388.5K | -1.08% | — | — |
| Mar 11, 2024 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 4,788 | $165.16 | $8.3B | -16.23% | +45.81% | $790.8K | -4.14% | — | — |
| Mar 8, 2024 | Sell | RGEN | Anthony Hunt | Chief Executive Officer | 16,708 | $197.43 | $8.3B | -16.23% | +45.81% | $3.3M | -0.96% | — | — |
| Mar 7, 2024 | Sell | RGEN | Christine Gebski | — | 386 | $195.72 | $8.3B | -16.23% | +45.81% | $75.5K | -1.37% | — | — |
| Mar 7, 2024 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 386 | $195.72 | $8.3B | -16.23% | +45.81% | $75.5K | -1.44% | — | — |
| Mar 7, 2024 | Sell | RGEN | James Bylund | Chief Operating Officer | 1,206 | $195.72 | $8.3B | -16.23% | +45.81% | $236.0K | -5.42% | — | — |
| Mar 7, 2024 | Sell | RGEN | Anthony Hunt | Chief Executive Officer | 2,867 | $195.72 | $8.3B | -16.23% | +45.81% | $561.1K | -1.40% | — | — |
| Mar 4, 2024 | Sell | RGEN | Christine Gebski | — | 131 | $193.99 | $8.3B | -16.23% | +45.81% | $25.4K | -0.46% | — | — |
| Mar 4, 2024 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 135 | $193.99 | $8.3B | -16.23% | +45.81% | $26.2K | -0.50% | — | — |
| Mar 4, 2024 | Sell | RGEN | James Bylund | Chief Operating Officer | 219 | $194.14 | $8.3B | -16.23% | +45.81% | $42.5K | -0.49% | — | — |
| Mar 4, 2024 | Sell | RGEN | Anthony Hunt | Chief Executive Officer | 8,386 | $195.32 | $8.3B | -16.23% | +45.81% | $1.6M | -1.97% | — | — |
| Mar 1, 2024 | Sell | RGEN | Ralf Kuriyel | Senior VP, R&D | 453 | $191.79 | $8.3B | -16.23% | +45.81% | $86.9K | -1.65% | — | — |
| Mar 1, 2024 | Sell | RGEN | James Bylund | Chief Operating Officer | 820 | $191.79 | $8.3B | -16.23% | +45.81% | $157.3K | -3.53% | — | — |
| Mar 1, 2024 | Sell | RGEN | Christine Gebski | — | 908 | $192.26 | $8.3B | -16.23% | +45.81% | $174.6K | -1.57% | — | — |
| Mar 1, 2024 | Sell | RGEN | Anthony Hunt | Chief Executive Officer | 3,322 | $191.79 | $8.3B | -16.23% | +45.81% | $637.1K | -1.53% | — | — |
| Feb 23, 2024 | Sell | RGEN | James Bylund | Chief Operating Officer | 5,313 | $179.72 | $8.3B | -16.23% | +45.81% | $954.9K | -8.57% | — | — |
| Nov 14, 2023 | Sell | RGEN | Anthony Hunt | Chief Executive Officer | 1,000 | $153.79 | $8.3B | -16.23% | +45.81% | $153.8K | -0.51% | — | — |
| Nov 10, 2023 | Sell | RGEN | Christine Gebski | — | 3,788 | $147.13 | $8.3B | -16.23% | +45.81% | $557.3K | -11.63% | — | — |